Market accessRegistration and reimbursement are the most critical steps in the introduction of a new drug.
Registration and reimbursement are the most critical steps in the introduction of a new drug. Certainly in a country like the Netherlands, where patients are not used to a personal contribution for healthcare, obtaining full reimbursement is essential.
Titus Health Care, together with specialized business partners, makes an analysis of the registration and reimbursement possibilities and proposes various strategies to successfully implement the registration and reimbursement process. Her excellent relationships with opinion leaders in the gynaecological field and leading clinics are of great importance here.
Since 2014, Titus Health Care has been in possession of a pharmaceutical wholesale license, making it possible to independently import medicines from the E.U. and distribute them in the Netherlands.
Titus Health Care introduced Bemfola® in January 2015 (follitropin alpha) on the Dutch market.
From January 2015 to mid-2020, Titus Health Care was exclusive Sales Agent for Bemfola® on behalf of manufacturer. Gedeon Richter. Bemfola® is a recombinant follicle stimulating hormone and is used in anovulation or to stimulate multi-follicular development in women undergoing fertility treatments, such as IVF or ICSI. Bemfola® is supplied in a pre-filled pen for single use.